diclofenac/hyaluronic acid

Diclofenac/Hyaluronic Acid A Viewpoint by Jason K. Rivers Division of Dermatology, University of British Columbia, Vancouver, British Columbia, Canada The annual incidence of skin cancer is increas- ing and this is expected to continue into the next century due, in part, to our aging population. One type of pre-malignant skin lesion known as ‘actinic’ or ‘solar’ keratosis develops in fair-skinned people who have had excess exposure to sunlight. These spots appear as red scaling lesions on sun- exposed sites. As these lesions may evolve into skin cancer, it has been recommended that they be treated by destructive (e.g. excision, curettage, freezing) or topical chemotherapy (e.g. fluorouracil) modalities. However, the former method can only be used for isolated lesions, whereas the latter is often associated with an intense inflammatory tissue reaction at the site of the keratoses. Diclofenac 3% in hyaluronic acid 2.5% gel [HYAL CT1101 (Solerase ® ); Hyal Pharmaceutical Corporation] represents a class of drug that appears to offer a new approach to the treatment of actinic keratoses. On the basis of multicentre randomised studies, it would appear that this preparation can produce clinical cures in approximately 50% of patients after twice daily application for 2 to 3 months. Although at least 70% of people will experience a mild to moderate irritant-type skin reaction, there remain many individuals who will show a clearing of their keratosis without any significant skin irri- tation. This is a distinct advantage of HYAL CT1101 over other preparations and it is envisioned that this product could be used in those patients who do not tolerate other products either because of the associated tissue response or a lack of efficacy. Of interest, in all studies to date, it would appear that the main benefit of HYAL CT1101 is seen a month after the drug has been discontinued. The reason for this is unclear. Although the mechanism of action of HYAL CT1101 is unknown, it is hypoth- esised that the drug works by inhibiting angio- genesis or by improving immune surveillance. Like fluorouracil, this preparation is not indicated for use in established skin cancers. The role HYAL CT1101 has to play in other skin conditions, if any, has yet to be determined. ▲ GUEST COMMENTARIES Drugs & Aging 1999 14 (4): 320-321 1170-229X/99/0004-0320/$01.00/0 © Adis International Limited. All rights reserved.

Upload: jason-k

Post on 09-Dec-2016

212 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Diclofenac/Hyaluronic AcidA Viewpoint by Jason K. RiversDivision of Dermatology, University of BritishColumbia, Vancouver, British Columbia,Canada

The annual incidence of skin cancer is increas-ing and this is expected to continue into the nextcentury due, in part, to our aging population. Onetype of pre-malignant skin lesion known as ‘ac-tinic’ or ‘solar’ keratosis develops in fair-skinnedpeople who have had excess exposure to sunlight.These spots appear as red scaling lesions on sun-exposed sites. As these lesions may evolve intoskin cancer, it has been recommended that they betreated by destructive (e.g. excision, curettage,freezing) or topical chemotherapy (e.g. fluorouracil)modalities. However, the former method can onlybe used for isolated lesions, whereas the latter is oftenassociated with an intense inflammatory tissue re-action at the site of the keratoses.

Diclofenac 3% in hyaluronic acid 2.5% gel[HYAL CT1101 (Solerase®); Hyal PharmaceuticalCorporation] represents a class of drug that appearsto offer a new approach to the treatment of actinickeratoses. On the basis of multicentre randomised

studies, it would appear that this preparation canproduce clinical cures in approximately 50% of pa-tients after twice daily application for 2 to 3 months.Although at least 70% of people will experience amild to moderate irritant-type skin reaction, thereremain many individuals who will show a clearingof their keratosis without any significant skin irri-tation. This is a distinct advantage of HYAL CT1101over other preparations and it is envisioned that thisproduct could be used in those patients who do nottolerate other products either because of the associ-ated tissue response or a lack of efficacy.

Of interest, in all studies to date, it would appearthat the main benefit of HYAL CT1101 is seen amonth after the drug has been discontinued. Thereason for this is unclear. Although the mechanismof action of HYAL CT1101 is unknown, it is hypoth-esised that the drug works by inhibiting angio-genesis or by improving immune surveillance.Like fluorouracil, this preparation is not indicatedfor use in established skin cancers. The role HYALCT1101 has to play in other skin conditions, if any,has yet to be determined. ▲

GUEST COMMENTARIES Drugs & Aging 1999 14 (4): 320-3211170-229X/99/0004-0320/$01.00/0

HYALURONIC ACID - My Filler · HYALURONIC ACID Hyaluronic acid is an anionic, nonsulfated glycosaminoglycan distributed throughout con-nective, epithelial and neural tissues. It is

Hyaluronic Acid Face Serum · Hyaluronic Acid Face Serum Product Description Can Be Sold As $33.65 for a 1 ounce bottle Selling Points 1) Hyaluronic Acid holds more than 1000mL of

Episilk Pure Hyaluronic Acid Serum Review

Hyaluronic Acid Supplements For Skin Review

Determination of hyaluronic acid in pharmaceutical

Hyaluronic acid-methotrexate conjugate for targeted

Phenol Hyaluronic Acid Conjugates: Correlation of

SciVision Biotech Inc.PDF).pdf · SciVision Biotech Inc. The Leading Technology of Hyaluronic Acid ~ Dr.Chun-Chang Chen. 2 ... Hyaluronic acid-based viscosupplementation . Hyaluronic

Hyaluronic acid

Hyaluronic Acid 60C - Doctor's Best Vitamins · Hyaluronic Acid INGREDIENTS Doctor’s Best Hyaluronic Acid with Chondroitin Sulfate features BioCell Collagen®, a patented, award-winning

SINCLAIR PHARMA PLC - Perfectha® Hyaluronic Acid Dermal ......Hyaluronic acid (HA) ... Hyaluronic acids (HAs), the most used filler substances currently on the market worldwide, have